Open access
Open access
Powered by Google Translator Translator

Covid-19

Covid-19 breakthrough infections in vaccinated health care workers.

29 Jul, 2021 | 11:30h | UTC

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers – New England Journal of Medicine

 

Commentary on Twitter (thread – click for more)

 

COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection.

29 Jul, 2021 | 11:32h | UTC

COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection – BMC Infectious Diseases

 

Commentary on Twitter

 

COVID vaccines slash viral spread, but Delta is an unknown – “Studies show that vaccines reduce the spread of SARS-CoV-2 by more than 80%, but the Delta variant is creating fresh uncertainty”.

29 Jul, 2021 | 11:21h | UTC

COVID vaccines slash viral spread – but Delta is an unknown – Nature

 

What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination.

29 Jul, 2021 | 11:28h | UTC

What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination – The Conversation

 

Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show.

29 Jul, 2021 | 11:19h | UTC

Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show – STAT

Original study (preprint): Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine – medRxiv

 

Commentary on Twitter (thread – click for more)

 

CDC changes mask guidance in response to threat of Delta variant of Covid-19.

28 Jul, 2021 | 10:23h | UTC

Commentary: CDC changes mask guidance in response to threat of Delta variant of Covid-19 – CNN

See guidance: Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage – Centers for Disease Control and Prevention

 

Commentaries on Twitter

 

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees.

28 Jul, 2021 | 10:19h | UTC

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis – The Lancet

Related:

WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

Case series: therapeutic plasma exchange in 3 patients with vaccine-induced immune thrombotic thrombocytopenia.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.

Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.

Case series: Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.

Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

[Preprint] Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine – Overall risk is 1 in 139,000; for age 65 and over, about 1 in 1,000,000; for age under 55, between 1 in 20,000 to 60,000.

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Editorial: SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – “The very low prevalence of this complication of vaccination, however severe, relative to the benefits of preventing Covid-19 must be emphasized”

Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

 

Commentary on Twitter

 

Editorial: Nine lessons learned from the Covid-19 pandemic for improving hospital care and health care delivery.

28 Jul, 2021 | 10:17h | UTC

Nine Lessons Learned From the COVID-19 Pandemic for Improving Hospital Care and Health Care Delivery – JAMA Internal Medicine

 

Report: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers.

28 Jul, 2021 | 10:16h | UTC

News release: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers – Royal Academy of Engineering

Report: Infection Resilient Environments: Buildings that keep us healthy and safe – National Engineering Policy Centre

Related:

WHO: Roadmap to improve and ensure good indoor ventilation in the context of COVID-19

CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk

Guidance: Using Ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes

 

Commentary on Twitter

 

Household transmission of SARS-CoV-2 from children and adolescents.

28 Jul, 2021 | 10:08h | UTC

Household Transmission of SARS-CoV-2 from Children and Adolescents – New England Journal of Medicine

Related:

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose

Study: Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity

A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters

Report: SARS-CoV-2 setting-specific transmission rates. Households showed the highest transmission rates (21.1%). Asymptomatic infections do occur but much less efficiently than symptomatic infection.

CDC Report: Transmission of SARS-COV-2 infections in households

The household secondary attack rate of SARS-CoV-2: A rapid review

 

Commentary on Twitter

 

COVID-19 and mucormycosis superinfection: the perfect storm.

28 Jul, 2021 | 10:09h | UTC

COVID-19 and mucormycosis superinfection: the perfect storm – Infection

Related:

ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries.

The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – careful use of antibiotics and corticosteroids and closely monitoring blood glucose levels are some of the strategies suggested by the authors.

Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India – Uncontrolled diabetes mellitus was the most common underlying disease; improper glucocorticoid use was independently associated with the disease.

Opinion | “Doctors have been blamed for the rise in black fungus in India, but the COVID treatment guidelines could be contributing” – improper use of antibiotics and higher than usual doses of corticosteroids may be contributing to the emergence of mucormycosis and other fungal co-infections.

What is mucormycosis, the fungal infection affecting COVID patients in India?

[Preprint] The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries.

Mucormycosis: The ‘black fungus’ maiming Covid patients in India

Global Guideline for the Diagnosis and Management of Mucormycosis

 

SARS-COV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis.

28 Jul, 2021 | 10:13h | UTC

SARS-COV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis – American Journal of Obstetrics and Gynecology

 

Moral uncertainty: A case study of Covid-19.

28 Jul, 2021 | 10:05h | UTC

Moral uncertainty: A case study of Covid-19 – Patient Education and Counseling

 

Commentary on Twitter

 

Review: Long covid—mechanisms, risk factors, and management.

27 Jul, 2021 | 03:52h | UTC

Long covid—mechanisms, risk factors, and management – The BMJ

 

Commentary on Twitter

 

Major medical groups call for employers to mandate Covid-19 vaccines for health care workers.

27 Jul, 2021 | 03:44h | UTC

Major medical groups call for employers to mandate Covid-19 vaccines for health care workers – CNN

Original Document: Joint Statement in Support of COVID-19 Vaccine Mandates for All Workers in Health and Long-Term Care

 

Commentaries on Twitter

 

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

27 Jul, 2021 | 03:48h | UTC

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination – Nature Medicine

Commentary: A ‘mix and match’ approach to SARS-CoV-2 vaccination – Nature Medicine

Related:

WHO warns against mixing and matching COVID vaccines.

Germany issues world’s strongest recommendation for mixing Covid-19 vaccines.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 

[Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity.

27 Jul, 2021 | 03:50h | UTC

News release: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity – Newcastle University

Original Study (preprint): Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine

Commentaries:

Commentary: Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds – BMJ

Expert reaction to preprint from PITCH study looking at interval between two Pfizer vaccine doses, and antibody and T-cell responses – Science Media Centre

Related:

Debate: Should we delay second vaccine doses to give one dose of the Covid-19 vaccine to more people? (several texts on the subject)

 

Safety evaluation of the second dose of mRNA COVID-19 vaccines in patients with immediate reactions to the first dose.

27 Jul, 2021 | 03:42h | UTC

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose – JAMA Internal Medicine

Commentaries:

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose – Massachusetts General Hospital

No anaphylaxis after second dose of mRNA COVID vaccine, study finds – CIDRAP

 

Commentary on Twitter

 

Opinion | What does public health really mean? Lessons from covid-19.

27 Jul, 2021 | 03:46h | UTC

What does public health really mean? Lessons from covid-19 – The BMJ Opinion

 

Commentary on Twitter (thread – click for more)

 

[Preprint] Test-negative case-control study: Effectiveness of Oxford-AstraZeneca vaccine in older people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted effectiveness was 77.9% for symptomatic Covid-19, 87.6% against hospitalization, and 93.6% against death.

27 Jul, 2021 | 03:41h | UTC

Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil – medRxiv

 

Commentary on Twitter (thread – click for more)

 

[Preprint] Test-negative case-control study: Effectiveness of CoronaVac vaccine in older people during SARS-CoV-2 Gamma variant transmission in Brazil – Adjusted vaccine effectiveness was 41.6% for symptomatic Covid-19, 59.0% against hospitalizations and 71.4% against deaths.

27 Jul, 2021 | 03:39h | UTC

Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study – medRxiv

 

Commentary on Twitter (thread – click for more)

 

CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness.

27 Jul, 2021 | 03:38h | UTC

CoronaVac vaccine: its results are patchy, but the world can’t ignore its usefulness – The Conversation

Related:

RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.

Prospective national cohort in Chile showed CoronaVac effectiveness was 65.9% for symptomatic Covid-19, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

Perspective | Are Chinese COVID vaccines underperforming? a dearth of real-life studies leaves unanswered questions.

WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.

Brazilian town experiment shows mass vaccination can wipe out COVID-19.

WHO validates Sinovac-CoronaVac COVID-19 vaccine for emergency use and issues interim policy recommendations.

[Press release – not published yet] The city of Serrana in Brazil has seen a 95% drop in Covid-19 deaths after almost all adults were vaccinated with Chinese CoronaVac – The findings suggest the pandemic can be controlled after 75% of people are fully vaccinated.

[Not published yet] Observational study in Uruguay found CoronaVac reduced mortality by 97 percent – “In people who had received two doses, it reduced infection with the coronavirus by 57 percent and intensive care admissions by 95 percent”.

 

[Preprint] RCT: In patients with COVID-19 and severe hypoxia, dexamethasone 12 mg did NOT result in statistically significant improved outcomes compared to dexamethasone 6 mg – “Mortality at 28 days was 27.1% and 32.3% in patients assigned to 12 mg and 6 mg, respectively (adjusted relative risk 0.86, 99% CI, 0.68-1.08)”.

26 Jul, 2021 | 03:01h | UTC

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial – medRxiv

 

Cohort study: Neurological manifestations of SARS-CoV-2 infection in hospitalized children and adolescents in the UK – “around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection”.

26 Jul, 2021 | 02:58h | UTC

Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study – The Lancet Child & Adolescent Health

Commentaries:

Neuroinflammation triggered by SARS-CoV-2 infection: syndromes and therapies – The Lancet Child & Adolescent Health

New UK study reveals extent of brain complications in children hospitalized with COVID-19 – University of Liverpool

 

Commentary on Twitter

 

Large cohort study finds one in two hospitalized COVID-19 patients develop a complication.

26 Jul, 2021 | 03:00h | UTC

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study – The Lancet

Commentaries:

Landmark study finds one in two hospitalised COVID-19 patients develop a complication – National Institute for Health Research

In-hospital complications associated with COVID-19 – The Lancet

CV Complications Common in Hospitalized COVID-19 Patients – TCTMD

Almost Half of Patients Admitted With COVID-19 Have Complications – HealthDay

 

Commentary on Twitter (thread – click for more)

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.